EXHIBIT 4 Presentation and Disclosure Requirements						
Balance Sheet						
		xxx,xxx				
Income Statement						
• • • • • • • • • • • • • • • • • • • •	\$ xx,xxx \$ xx,xxx \$	XX,XXX XX,XXX				
(Fair-Value Method Only: Additional line item below is required) Other Expenses and Losses (Other Revenues and Gains) Premiums paid and changes in fair value for life settlement contracts (Note 5)	\$:	XXX,XXX				
Statement of Cash Flows						
Cash Flows from Operating Activities Investment income from life settlement contracts (Investment Method Only) Gain from proceeds received on life settlement contracts xx,xxx	\$	xx,xxx \$				
(Fair-Value Method Only) Premiums paid and changes in fair value for life settlement contracts	\$	XX,XXX				
Cash Flows from Investing Activities Purchase of life settlement contracts Premiums paid on life settlement contracts (Investment Method Only)	(\$	xxx,xxx) xx,xxx)				
Proceeds from life settlement contracts Proceeds from return of premiums on life settlement contracts		,xxx,xxx xx,xxx				

Note: Some entities treat investment trading activity as operating cash flows only.

Notes to the Financial Statements

Note 5: Investments in Life Settlement Contracts

InvestCo purchases life settlement contracts for long-term investment purposes and accounts for these investments under FSB FTB 85-4-1. InvestCo uses the investment method of accounting for some of the contracts and the fair value method for others. As of December 31, 20XX, InvestCo has the following investments in life settlement contracts:

Investment Method						
	Number of	Carrying	Premiums	Face Value		
Year	Contracts	Value	Payable	(Death Benefits)		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
Thereafter	XXX	\$xx,xxx,xxx	\$xxx,xxx	\$xxx,xxx,xxx		
Fair Value Method						
	Number of	Carrying	Premiums	Face Value		
Year	Contracts	Value	Payable	(Death Benefits)		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
20xx	XX	\$ xxx,xxx	\$ xx,xxx	\$ xx,xxx,xxx		
Thereafter	XXX	\$xx,xxx,xxx	\$xxx,xxx	\$xxx,xxx,xxx		

Fair value is estimated using good-faith estimates calculated by a valuation committee. The committee considered the following factors: cost at date of purchase; recent purchases and sales of similar investments; financial standing of the issuer; changes in economic conditions affecting the issuer; and standard, actuarially developed mortality tables.

For the fiscal years presented on the current income statement, years ended December 31, 20xx, 20xx, and 20xx, the investments experienced the following gains and losses:

Year	Realized Gains (Losses)	Unrealized Gains (Losses)
20xx	\$ xx,xxx	\$ xx,xxx
20xx	(\$ xx,xxx)	\$ xx,xxx
20xx	\$ xx,xxx	(\$x x,xxx)